Snowdome Foundation is incredibly fortunate to have the support of a Board of Directors and various committees that are made up entirely of volunteers.
We are delighted to share that eltranatamab, an immunotherapy drug, specifically known as a bispecific antibody will be made available later in 2025 for Australian myeloma patients.
2024 Cannon Family Travel Grant recipient, Dr Edward Cliff, a third-year clinical haematology registrar at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, recently attended the American Society of Haematology (ASH) Annual Meeting in California.
The Snowdome Foundation collaborates with world-leading blood cancer researchers to accelerate new therapies for Australian myeloma patients.
Supported by the Snowdome Foundation, A/Prof. Jane Oliaro is undertaking important work to improve the functionality of CAR-T cells for myeloma patients.
Snowdome co-founder and director, Prof. Miles Prince AM, received the Winsome Constance Kindness Award for his dedication to blood cancer research.
Earlier this year, the Snowdome Foundation supported a fellowship to optimise immunotherapy for aggressive lymphoma.
2022 Snowdome Haematology Fellow, Dr Josh Tobin provides an update on his research into biomarker-directed immunotherapy in advanced stage follicular lymphoma.
The Snowdome Foundation is pleased to announce that Dr Edward Cliff and Dr Hansen Kosasih have been awarded 2024 Cannon Family Travel Grants.